What is Laboratorios Farmaceuticos Rovi, S.A. (LABFF)?

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of LABFF?

The current price of LABFF is $67.17. Prices are updated in real time on Stocks360.

What is LABFF's price-to-earnings (PE) ratio?

LABFF's trailing twelve-month PE ratio is 17.00, based on current price and earnings per share data available on Stocks360.

What is LABFF's market capitalization?

LABFF's market capitalization is $3,435,277,728.00, placing it in the mid-cap tier.

Does LABFF pay a dividend?

Yes. LABFF has a trailing twelve-month dividend yield of 0.02%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Laboratorios Farmaceuticos Rovi, S.A. (LABFF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$67.17

Market Cap

$3.44B

PE (TTM)

17.00

EPS (TTM)

N/A

Dividend Yield

1.56%

Beta

0.23

Day Range

$67.17 – $90.61

52-wk Range

$67.17 – $90.61

Avg Volume

N/A

Volume

100.00

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) is a publicly traded company in the Healthcare sector. Latest price: $67.17. Market cap $3.44B. Trailing PE 17.00. Dividend yield 1.56%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $90.61 2026-10-26 · $67.17 (-25.87%)

Earnings

Most Recent

Feb 23, 2022

EPS $1.12 vs est. $0.69

Beat by $0.43

Next Earnings

Nov 5, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical firm actively involved in the discovery, creation, manufacturing, and commercialization of medicinal products. Its market presence extends across Spain, the European Union, OECD nations, and other international territories. Beyond its proprietary portfolio, Rovi also distributes pharmaceutical offerings under license from other companies. Rovi's diverse product lineup addresses several critical health conditions. Key offerings include Hibor and Becat (an Enoxaparin biosimilar), both low-molecular-weight heparins employed in preventing and managing venous thromboembolic disorders. Neparvis targets symptomatic chronic heart failure with reduced ejection fraction in adults. For hypercholesterolemia, the company offers Absorcol, Vytorin, and Orvatez. Respiratory ailments like chronic obstructive pulmonary diseases (COPD) are treated with long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is prescribed for men experiencing moderate to severe storage and voiding symptoms due to benign prostatic hyperplasia (BPH) who have not responded sufficiently to single-drug therapies. Additionally, Medikin…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	17.00×
P/S (TTM)	4.07×
P/B	4.49×
P/FCF (TTM)	17.81×
EV / EBITDA	11.76×
EV / Sales	4.05×
Earnings Yield	5.88%
Free Cash Flow Yield	5.62%
Dividend Yield	1.56%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$3.13B
Revenue (TTM)	$773.05M
Net Income (TTM)	$185.16M
Free Cash Flow (TTM)	$180.63M
Net Debt	-$19.28M
Working Capital	$291.41M
Gross Margin	64.02%
Operating Margin	21.97%
Net Margin	23.95%
Return on Equity	27.84%
Return on Invested Capital	15.22%